US2017283775A1PendingUtilityA1

Compositions and Methods for Treatment of Cancer

67
Assignee: UNIV PENNSYLVANIAPriority: Dec 9, 2010Filed: Nov 17, 2016Published: Oct 5, 2017
Est. expiryDec 9, 2030(~4.3 yrs left)· nominal 20-yr term from priority
Inventors:Carl H. JuneBruce L. LevineDavid L. PorterMichael D. KalosMichael C. Milone
A61P 37/02A61P 43/00A61P 35/00A61P 37/04A61P 35/02C07K 2319/02C07K 16/3061A61K 39/39558C12N 2740/15071C07K 2317/622C12N 15/86C07K 14/70578C12N 2510/00A61K 38/1774C07K 14/7051C07K 2319/03C12N 2740/15034A61K 2039/585C12N 7/00C12N 15/85C07K 16/2803C07K 2317/80C07K 2317/76C07K 2319/74A61K 38/177A61K 2039/5256A61K 48/005C07K 2319/33C07K 14/075C07K 14/70521C12N 2501/51C12N 2740/15043A61K 2039/505C07K 16/30C12N 2501/515C07K 14/70507C07K 2319/30C07K 14/70503C07K 2319/00A61K 45/06C07K 2317/53C07K 14/70596C07K 14/525C07K 14/70517C07K 16/2896C12N 15/861A61K 2039/5158C12N 5/0636A61K 40/31A61K 40/11A61K 40/4211A61K 2239/38A61K 2239/48A61K 2239/31A61K 39/39
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

Claims

exact text as granted — not AI-modified
1 . A human memory T cell comprising a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the human memory T cell is of a human having cancer. 
     
     
         2 . The human memory T cell of  claim 1 , wherein the CD19 antigen binding domain is a Fab or scFv. 
     
     
         3 . The human memory T cell of  claim 2 , wherein the CD19 antigen binding domain is a scFv. 
     
     
         4 . The human memory T cell of  claim 1 , wherein the transmembrane domain comprises CD8 transmembrane domain. 
     
     
         5 . The human memory T cell of  claim 1 , wherein the co-stimulatory signaling region is CD27 or 4-1BB. 
     
     
         6 . The human memory T cell of  claim 1 , wherein the CAR further comprises a hinge region. 
     
     
         7 . The human memory T cell of  claim 6 , wherein the hinge region comprises a CD8α hinge region. 
     
     
         8 . A human memory T cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the human memory T cell is of a human having cancer. 
     
     
         9 . The human memory T cell of  claim 8 , wherein the CD19 antigen binding domain is a Fab or scFv. 
     
     
         10 . The human memory T cell of  claim 9 , wherein the CD19 antigen binding domain is a scFv. 
     
     
         11 . The human memory T cell of  claim 8 , wherein the transmembrane domain comprises CD8 transmembrane domain. 
     
     
         12 . The human memory T cell of  claim 8 , wherein the co-stimulatory signaling region is CD27 or 4-1BB. 
     
     
         13 . The human memory T cell of  claim 8 , wherein the CAR further comprises a hinge region. 
     
     
         14 . The human memory T cell of  claim 13 , wherein the hinge region comprises a CD8α hinge region. 
     
     
         15 . A persisting population of human T cells comprising a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human having cancer. 
     
     
         16 . The persisting population of human T cells of  claim 15 , wherein the CD19 antigen binding domain is a Fab or scFv. 
     
     
         17 . The persisting population of human T cells of  claim 16 , wherein the CD19 antigen binding domain is a scFv. 
     
     
         18 . The persisting population of human T cells of  claim 15 , wherein the transmembrane domain comprises CD8 transmembrane domain. 
     
     
         19 . The persisting population of human T cells of  claim 15 , wherein the co-stimulatory signaling region is CD27 or 4-1BB. 
     
     
         20 . The persisting population of human T cells of  claim 15 , wherein the CAR further comprises a hinge region. 
     
     
         21 . The persisting population of human T cells of  claim 20 , wherein the hinge region comprises a CD8α hinge region. 
     
     
         22 . A persisting population of human T cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human having cancer. 
     
     
         23 . The persisting population of human T cells of  claim 22 , wherein the CD19 antigen binding domain is a Fab or scFv. 
     
     
         24 . The persisting population of human T cells of  claim 23 , wherein the CD19 antigen binding domain is a scFv. 
     
     
         25 . The persisting population of human T cells of  claim 22 , wherein the transmembrane domain comprises CD8 transmembrane domain. 
     
     
         26 . The persisting population of human T cells of  claim 22 , wherein the co-stimulatory signaling region is CD27 or 4-1BB. 
     
     
         27 . The persisting population of human T cells of  claim 22 , wherein the CAR further comprises a hinge region. 
     
     
         28 . The persisting population of human T cells of  claim 27 , wherein the hinge region comprises a CD8α hinge region.

Join the waitlist — get patent alerts

Track US2017283775A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.